HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe
People with HIV-1 infection who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include > 2 active drugs.
Emerging Treatments In HIV
Fostemsavir Active in Multidrug-Resistant HIV-1 Infection
Reduction in HIV-1 RNA level significantly greater for fostemsavir versus placebo in randomized cohort.
Telmisartan Adjunct Treatment May Reduce CNS Inflammation During Acute HIV
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
DUALIS Results Show Switch to 2-Drug Regimen Is Effective in Patients With HIV
Results from the DUALIS study demonstrated that dual therapy with dolutegravir and boosted darunavir tended to be an effective treatment option with no treatment-emergent resistance for people with HIV.
New Long-Acting Two-Drug Injectable Regimen for Maintaining HIV Suppression
Therapy with monthly injection of long-acting cabotegravir plus rilpivirine was noninferior to once-daily oral therapy for maintaining HIV-1 suppression.
HIV Therapy Symtuza Approved for Use in Pediatric Patients
Symtuza is a 4-drug combination of darunavir, an HIV-1 protease inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide.
Serum HIV Neutralization Prediction After Antibody Treatment
Research has identified 3 approaches that may satisfactorily predict serum neutralization of HIV infection and may result in more efficient use of serum samples identified.
Addition of Auranofin to ART for HIV-1 Eradication
The gold salt auranofin may be a promising addition to antiretroviral therapy (ART) to target individuals categorized as latent viral reservoirs of HIV-1.
NDA Submitted for Potential First-in-Class HIV Therapy
The NDA for a first-in-class HIV-1 attachment inhibitor for the treatment of HIV-1 infection has been submitted to the FDA.
New Federal Program Provides Free HIV Prevention Drugs to Uninsured
Expanding access to PrEP is key part of government’s aim of ending nation’s HIV epidemic by 2030
- Loading...
Loading...
Next post in HIV/AIDS
Loading... 
Loading...